Literature DB >> 30185360

Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients.

Sultan Pınar Çetintepe1, Taşkın Şentürk2, Gökhan Sargın2, Neriman Aydın3.   

Abstract

OBJECTIVE: T cell abnormal activation is thought to have a main role in the etiology of ankylosing spondylitis (AS). While cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is suppressing the immune system, in previous studies serum soluble CTLA-4 (sCTLA-4) was detected at high amounts in autoimmune disorders. We sought to evaluate the association between soluble CTLA-4 in serum and disease activity in AS patients.
METHODS: Thirty-eight patients with AS, 28 rheumatoid arthritis (RA) patients, and 27 disease-free controls were enrolled to the study. The levels of sCTLA-4 were determined for each participant using an enzyme-linked immunosorbent assay. The erythrocyte sedimentation rate (ESR), C-reactive peptide, and demographic characteristics were documented. The data were analyzed by using relevant statistical methods.
RESULTS: In comparison with RA patients and controls, patients with AS showed high sCTLA-4 levels (p<0.001). The sCTLA-4 levels did not correlate with the severity of the disease in AS patients (p=0.370). The ESR levels and Bath Ankylosing Spondylitis Disease Activity Index were correlated in AS patients (p=0.012).
CONCLUSION: We evaluated the association between the disease severity of AS and sCTLA-4. Although, the correlation was not shown, sCTLA-4 was highest in the AS group. Further studies with larger samples should be completed to attain a better understanding of the AS etiology.

Entities:  

Year:  2018        PMID: 30185360      PMCID: PMC6072698          DOI: 10.5152/eurjrheum.2018.17114

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  19 in total

Review 1.  CD28/B7 system of T cell costimulation.

Authors:  D J Lenschow; T L Walunas; J A Bluestone
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

2.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

3.  Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease.

Authors:  M K Oaks; K M Hallett
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

4.  Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence.

Authors:  Xiong-Biao Wang; Maria Kakoulidou; Ricardo Giscombe; Qianhui Qiu; DeRen Huang; Ritva Pirskanen; Ann Kari Lefvert
Journal:  J Neuroimmunol       Date:  2002-09       Impact factor: 3.478

Review 5.  HLA-B27 and the pathogenesis of spondyloarthritis.

Authors:  M Ramos; J A López de Castro
Journal:  Tissue Antigens       Date:  2002-09

6.  Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis.

Authors:  Ju Cao; Lin Zou; Peixin Luo; Pu Chen; Liping Zhang
Journal:  Int Immunopharmacol       Date:  2012-08-20       Impact factor: 4.932

7.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

9.  CTLA-4 ligation blocks CD28-dependent T cell activation.

Authors:  T L Walunas; C Y Bakker; J A Bluestone
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

10.  Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.

Authors:  Eric Toussirot; Philippe Saas; Marina Deschamps; Fabienne Pouthier; Lucille Perrot; Sylvain Perruche; Jacqueline Chabod; Pierre Tiberghien; Daniel Wendling
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

View more
  2 in total

1.  Serum sCTLA-4 level is not associated with type 1 diabetes or the coexistence of autoantibodies in children and adolescent patients from the southern region of Saudi Arabia.

Authors:  Ahmed Al-Hakami
Journal:  Auto Immun Highlights       Date:  2020-12-03

2.  CD96 Downregulation Promotes the Immune Response of CD4 T Cells and Associates with Ankylosing Spondylitis.

Authors:  Fengqing Wu; Huan Yang; Xiao Xu; Conglin Ren; Yang Zheng; Helou Zhang; Bingbing Cai; Rui Qiu; Weifan Ren; Renfu Quan
Journal:  Biomed Res Int       Date:  2022-06-19       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.